Ovarian cancer is the deadliest cancer of the female reproductive system. About 80% of patients relapse after initial chemotherapy, and most recurrent cases develop multidrug resistance. Standard treatment uses platinum-based drugs to damage DNA and paclitaxel to stop cell division, but cancer cells often adapt and survive.
This resistance is largely driven by cytokines—signaling proteins in the tumor microenvironment. IL-6 is a major driver, activating survival pathways that block cell death. Other cytokines such as IL-11, IL-8, TGF-β, TNF-α, and VEGF help cancer cells pump out drugs, avoid apoptosis, spread more easily, and build new blood vessels to feed the tumor.
Researchers are now testing treatments that block these signals. Antibodies like Siltuximab and Tocilizumab aim to disrupt IL-6 signaling, while other experimental drugs and natural compounds target related survival pathways. By breaking this communication network, scientists hope to prevent relapse and restore the effectiveness of chemotherapy.